Profluent announced a multi-program partnership with Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines. The deal underscores growing demand for AI-enabled drug discovery and is a meaningful validation of Profluent’s platform, with potential long-term upside if programs advance successfully.
Profluent announced a multi-program partnership with Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines. The deal underscores growing demand for AI-enabled drug discovery and is a meaningful validation of Profluent’s platform, with potential long-term upside if programs advance successfully.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
